BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Press Releases

  Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million

  September 28, 2026

   · 

  7 min read
• Press Releases

  Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs

  September 28, 2026

   · 

  14 min read
• Press Releases

  AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

  September 28, 2026

   · 

  6 min read
• Press Releases

  U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

  September 28, 2026

   · 

  7 min read
• Press Releases

  CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

  September 28, 2026

   · 

  8 min read
• Press Releases

  SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

  September 28, 2026

   · 

  6 min read
• Press Releases

  Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

  September 28, 2026

   · 

  6 min read
• Press Releases

  Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

  September 28, 2026

   · 

  9 min read
• Press Releases

  Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

  September 28, 2026

   · 

  18 min read
• 

  Approvals

  AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

  In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.

  September 28, 2026

   · 

  2 min read

   · 

  Tristan Manalac